Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by <it>Mycobacterium avium </it>complex prophylaxis in HIV

<p>Abstract</p> <p>Background</p> <p>Our goal was to illustrate a method for making indirect treatment comparisons in the absence of head-to-head trials, by portraying the derivation of published efficacies for prophylaxis regimens of HIV-related opportunistic infection...

Full description

Bibliographic Details
Main Authors: Freedberg Kenneth A, Sloan Caroline E, Chu Jennifer, Yazdanpanah Yazdan, Losina Elena
Format: Article
Language:English
Published: BMC 2011-03-01
Series:AIDS Research and Therapy
Online Access:http://www.aidsrestherapy.com/content/8/1/14
_version_ 1828497317008769024
author Freedberg Kenneth A
Sloan Caroline E
Chu Jennifer
Yazdanpanah Yazdan
Losina Elena
author_facet Freedberg Kenneth A
Sloan Caroline E
Chu Jennifer
Yazdanpanah Yazdan
Losina Elena
author_sort Freedberg Kenneth A
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Our goal was to illustrate a method for making indirect treatment comparisons in the absence of head-to-head trials, by portraying the derivation of published efficacies for prophylaxis regimens of HIV-related opportunistic infections.</p> <p>Results</p> <p>We identified published results of randomized controlled trials from the United States in which HIV-infected patients received rifabutin, azithromycin, clarithromycin, or placebo for prophylaxis against <it>Mycobacterium avium </it>complex (MAC). We extracted the number of subjects, follow-up time, primary MAC events, mean CD4 count, and proportion of subjects on mono or dual antiretroviral therapy (ART) from each study. We derived the efficacy of each drug using adjusted indirect comparisons and, when possible, by direct comparisons. Five articles satisfied our inclusion criteria. Using direct comparison, we estimated the efficacies of rifabutin, clarithromycin, and azithromycin compared to placebo to be 53% (95% CI, 48-61%), 66% (95% CI, 61-74%), and 66% (95% CI, 60-81%), respectively. Using adjusted indirect calculations, the efficacy of rifabutin compared to placebo ranged from 41% to 44%. The adjusted indirect efficacies of clarithromycin and azithromycin were estimated to be 73% and 72%, respectively.</p> <p>Conclusions</p> <p>Accurate estimates of specific drug dosages as compared to placebo are important for policy and implementation research. This study illustrates a simple method of adjusting for differences in study populations by using indirect comparisons in the absence of head-to-head HIV clinical trials.</p>
first_indexed 2024-12-11T12:46:29Z
format Article
id doaj.art-367daba4a97c4ccbb6c68e83591adf94
institution Directory Open Access Journal
issn 1742-6405
language English
last_indexed 2024-12-11T12:46:29Z
publishDate 2011-03-01
publisher BMC
record_format Article
series AIDS Research and Therapy
spelling doaj.art-367daba4a97c4ccbb6c68e83591adf942022-12-22T01:06:49ZengBMCAIDS Research and Therapy1742-64052011-03-01811410.1186/1742-6405-8-14Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by <it>Mycobacterium avium </it>complex prophylaxis in HIVFreedberg Kenneth ASloan Caroline EChu JenniferYazdanpanah YazdanLosina Elena<p>Abstract</p> <p>Background</p> <p>Our goal was to illustrate a method for making indirect treatment comparisons in the absence of head-to-head trials, by portraying the derivation of published efficacies for prophylaxis regimens of HIV-related opportunistic infections.</p> <p>Results</p> <p>We identified published results of randomized controlled trials from the United States in which HIV-infected patients received rifabutin, azithromycin, clarithromycin, or placebo for prophylaxis against <it>Mycobacterium avium </it>complex (MAC). We extracted the number of subjects, follow-up time, primary MAC events, mean CD4 count, and proportion of subjects on mono or dual antiretroviral therapy (ART) from each study. We derived the efficacy of each drug using adjusted indirect comparisons and, when possible, by direct comparisons. Five articles satisfied our inclusion criteria. Using direct comparison, we estimated the efficacies of rifabutin, clarithromycin, and azithromycin compared to placebo to be 53% (95% CI, 48-61%), 66% (95% CI, 61-74%), and 66% (95% CI, 60-81%), respectively. Using adjusted indirect calculations, the efficacy of rifabutin compared to placebo ranged from 41% to 44%. The adjusted indirect efficacies of clarithromycin and azithromycin were estimated to be 73% and 72%, respectively.</p> <p>Conclusions</p> <p>Accurate estimates of specific drug dosages as compared to placebo are important for policy and implementation research. This study illustrates a simple method of adjusting for differences in study populations by using indirect comparisons in the absence of head-to-head HIV clinical trials.</p>http://www.aidsrestherapy.com/content/8/1/14
spellingShingle Freedberg Kenneth A
Sloan Caroline E
Chu Jennifer
Yazdanpanah Yazdan
Losina Elena
Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by <it>Mycobacterium avium </it>complex prophylaxis in HIV
AIDS Research and Therapy
title Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by <it>Mycobacterium avium </it>complex prophylaxis in HIV
title_full Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by <it>Mycobacterium avium </it>complex prophylaxis in HIV
title_fullStr Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by <it>Mycobacterium avium </it>complex prophylaxis in HIV
title_full_unstemmed Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by <it>Mycobacterium avium </it>complex prophylaxis in HIV
title_short Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by <it>Mycobacterium avium </it>complex prophylaxis in HIV
title_sort drug efficacy by direct and adjusted indirect comparison to placebo an illustration by it mycobacterium avium it complex prophylaxis in hiv
url http://www.aidsrestherapy.com/content/8/1/14
work_keys_str_mv AT freedbergkennetha drugefficacybydirectandadjustedindirectcomparisontoplaceboanillustrationbyitmycobacteriumaviumitcomplexprophylaxisinhiv
AT sloancarolinee drugefficacybydirectandadjustedindirectcomparisontoplaceboanillustrationbyitmycobacteriumaviumitcomplexprophylaxisinhiv
AT chujennifer drugefficacybydirectandadjustedindirectcomparisontoplaceboanillustrationbyitmycobacteriumaviumitcomplexprophylaxisinhiv
AT yazdanpanahyazdan drugefficacybydirectandadjustedindirectcomparisontoplaceboanillustrationbyitmycobacteriumaviumitcomplexprophylaxisinhiv
AT losinaelena drugefficacybydirectandadjustedindirectcomparisontoplaceboanillustrationbyitmycobacteriumaviumitcomplexprophylaxisinhiv